Segall Bryant & Hamill’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$880K Hold
105,980
0.01% 521
2025
Q4
$1.31M Buy
105,980
+25,131
+31% +$269K 0.02% 481
2025
Q3
$713K Buy
+80,849
New +$629K 0.01% 524
2016
Q4
Sell
-18,349
Closed -$579K 545
2016
Q3
$579K Buy
18,349
+78
+0.4% +$2.27K 0.01% 390
2016
Q2
$514K Buy
18,271
+1,185
+7% +$46.5K 0.01% 412
2016
Q1
$621K Buy
17,086
+3,950
+30% +$140K 0.02% 392
2015
Q4
$526K Sell
13,136
-15
-0.1% -$523 0.01% 402
2015
Q3
$375K Sell
13,151
-7,121
-35% -$235K 0.01% 449
2015
Q2
$668K Sell
20,272
-124,386
-86% -$3.86M 0.02% 386
2015
Q1
$4.16M Sell
144,658
-198,444
-58% -$5.69M 0.09% 238
2014
Q4
$9.34M Buy
343,102
+43,022
+14% +$1.03M 0.21% 148
2014
Q3
$6.39M Buy
300,080
+132,244
+79% +$3.03M 0.15% 178
2014
Q2
$3.77M Sell
167,836
-17,395
-9% -$405K 0.09% 217
2014
Q1
$4.68M Sell
185,231
-485
-0.3% -$12.3K 0.11% 205
2013
Q4
$4.27M Sell
185,716
-5,595
-3% -$117K 0.1% 210
2013
Q3
$3.64M Buy
191,311
+8,236
+4% +$147K 0.09% 219
2013
Q2
$2.64M Buy
+183,075
New +$2.65M 0.07% 241

Other funds holding EBS

Segall Bryant & Hamill's EBS Position: Q1 2026 in Review

Segall Bryant & Hamill held its Emergent Biosolutions (EBS) position steady in Q1 2026 at 105,980 shares worth $880K. The position accounts for 0.01% of the portfolio, ranked #521.

Segall Bryant & Hamill first reported a position in EBS in Q2 2013 and has held it in 17 quarters since. The position peaked at $9.34M in Q4 2014. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Segall Bryant & Hamill held 105,980 shares of Emergent Biosolutions worth $880K as of Q1 2026.
  • Segall Bryant & Hamill left its Emergent Biosolutions share count unchanged in Q1 2026.
  • Emergent Biosolutions made up 0.01% of Segall Bryant & Hamill's portfolio in Q1 2026, its #521 holding.
  • Segall Bryant & Hamill first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 17 quarters since.
  • Segall Bryant & Hamill's Emergent Biosolutions position peaked at $9.34M in Q4 2014.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.